Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of OCS-05 in Patients with Acute Optic Neuritis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Privosegtor (Primary) ; Corticosteroid
Indications Optic neuritis
Focus Adverse reactions; First in man; Proof of concept
Acronyms ACUITY
Sponsors Accure Therapeutics; Oculis Pharma

Most Recent Events

29 Oct 2026 According to an Oculis Pharma media release, data from phase II ACUITY trial will be presented at the 6th Asia-Pacific Ophthalmic Innovation Society Congress and the CNS Summit on November 2nd and 3rd 2026..
22 Oct 2026 According to an Oculis Pharma media release, data from the trial were presented during the 10th Joint ACTRIMS-ECTRIMS Meeting, MSToronto 2026.
22 Oct 2026 Results presented in the Oculis Pharma Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com